Literature DB >> 25857654

"There Are No Known Benefits . . .": Considering the Risk/Benefit Ratio of Qualitative Research.

Tara Opsal1, Jennifer Wolgemuth2, Jennifer Cross3, Tanya Kaanta4, Ellyn Dickmann5, Soria Colomer2, Zeynep Erdil-Moody2.   

Abstract

Institutional review boards (IRBs) are responsible for weighing the risks and benefits of research participation. Qualitative researchers note numerous instances where IRB ethical frameworks fail to align with the ethics of their research projects and point out that IRB understandings of the benefits and risks of research often differ from those of the participants they seek to protect. This qualitative cross-case research investigates participants' interview experiences in six qualitative studies that differed in their methods, subject of focus, and populations. Our findings indicate that contemporary IRBs' use of population "vulnerability" and topic "sensitivity" to assess project risk does not adequately determine the benefits, risks, or ethicality of research. We recommend that IRBs treat as real the evidence for benefits in qualitative research, recognize that sensitivity and vulnerability do not predict risk, and encourage researchers to attend to relationships in their projects.
© The Author(s) 2015.

Entities:  

Keywords:  ethics / moral perspectives; qualitative; reflexivity; sensitive topics; vulnerable populations

Mesh:

Year:  2015        PMID: 25857654     DOI: 10.1177/1049732315580109

Source DB:  PubMed          Journal:  Qual Health Res        ISSN: 1049-7323


  2 in total

1.  The insight and challenge of reflexive practice in an ethnographic study of black traumatically injured patients in Philadelphia.

Authors:  Sara F Jacoby
Journal:  Nurs Inq       Date:  2016-11-15       Impact factor: 2.393

2.  Disclosure of non-recent (historic) childhood sexual abuse: What should researchers do?

Authors:  Sergio A Silverio; Susan Bewley; Elsa Montgomery; Chelsey Roberts; Yana Richens; Fay Maxted; Jane Sandall; Jonathan Montgomery
Journal:  J Med Ethics       Date:  2020-11-10       Impact factor: 2.903

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.